Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M, Postorino M, Gallo GA, Messina G, Neri S, Piro E, Gentile M, Moscato T, Monteleone R, Fedele R, Mazzone C, Console G, Penna G, Alati C, Vincelli ID, Irrera G, Musolino C, Ronco F, Molica S, Morabito F. Martino M, et al. Among authors: fedele r. Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):148-54. doi: 10.1016/j.clml.2013.11.009. Epub 2013 Nov 22. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24417912
Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.
Martino M, Olivieri A, Offidani M, Vigna E, Moscato T, Fedele R, Montanari M, Console G, Gentile M, Messina G, Irrera G, Morabito F. Martino M, et al. Among authors: fedele r. Expert Opin Investig Drugs. 2013 May;22(5):619-34. doi: 10.1517/13543784.2013.788643. Epub 2013 Apr 4. Expert Opin Investig Drugs. 2013. PMID: 23550793 Review.
Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen.
Fedele R, Messina G, Martinello T, Gallo GA, Pontari A, Moscato T, Console G, Dattola A, Princi D, Cuzzola M, Alati C, Ronco F, Molica S, Irrera G, Martino M. Fedele R, et al. Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):493-500. doi: 10.1016/j.clml.2014.04.006. Epub 2014 Jun 11. Clin Lymphoma Myeloma Leuk. 2014. PMID: 25034142
Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
Martino M, Recchia AG, Moscato T, Fedele R, Neri S, Gentile M, Alati C, Vincelli ID, Piro E, Penna G, Musolino C, Ronco F, Molica S, Morabito F. Martino M, et al. Among authors: fedele r. Cytotherapy. 2015 Oct;17(10):1485-93. doi: 10.1016/j.jcyt.2015.05.010. Epub 2015 Jul 15. Cytotherapy. 2015. PMID: 26188967
The role of tandem stem cell transplantation for multiple myeloma patients.
Martino M, Recchia AG, Fedele R, Neri S, Vincelli ID, Moscato T, Gentile M, Morabito F. Martino M, et al. Among authors: fedele r. Expert Opin Biol Ther. 2016;16(4):515-34. doi: 10.1517/14712598.2016.1136285. Epub 2016 Feb 6. Expert Opin Biol Ther. 2016. PMID: 26698133 Review.
83 results